Abstract. A major problem in the assessment of circulating B lymphocytes in multiple myeloma is the extent to which cells with passively absorbed Ig contribute to the assay. We have analyzed peripheral blood B cell numbers in 51 patients in various treatment categories by using an assay that is not subject to artifacts involving cytophilic Ig. We have defined a B lymphocyte by three different criteria (a) expression of a high surface density of Ig (b) expression of a high density of HLA.DR and (c) expression of a marker exclusive to surface Ig' B cells. By these criteria, normal individuals have an average of 6% B cells. In multiple myeloma patients, B cell levels in purified mononuclear cell preparations are severely reduced. Untreated patients and the majority of patients on intermittent chemotherapy have 20-600-fold fewer B cells than do normal donors (average = 0.3%). This decrease was even greater in whole blood of patients as compared with normal donors (100-1,000-fold fewer B cells). The number of B cells did not correlate with disease status or paraprotein concentration. We found no evidence to support the idea that B lymphocytes in patients include a substantial monoclonal subset.
Introduction
A deficiency both of normal polyclonal immunoglobulins and functional immunity is common in patients with multiple myeloma (1) (2) (3) (4) (5) (6) . One potential mechanism is a deficiency of normal B cells. Investigations of B cell number in peripheral blood have yielded confficting information. Increased, normal, and reduced polyclonal B cell numbers have all been described Receivedfor publication 6 December 1983 and in revisedform 24 May 1984. (7) (8) (9) (10) (11) (12) (13) (14) . Both an expanded monoclonal lymphocyte pool and an absence of monoclonal lymphocytes related to the malignant plasma cells have also been reported (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) .
There are two major problems in the study of peripheral blood lymphocytes of patients with multiple myeloma. First Anti-idiotypic antibody was produced by immunization of mice with monoclonal protein that had been purified on protein A or DEAE-columns. The IgG fraction of serum was passed one to two times through Sepharose 4B (Pharmacia Fine Chemicals, Dorval, Quebec) coupled with eight different monoclonal proteins and HGG as described (6) , to remove antibody directed against common determinants on Ig and assayed in enzyme-linked immunosorbent assay for specificity.
Results
B cells in normal PBL. B cells were defined as those cells able to form polar caps as described in the methods. Essentially all cells able to bind our reagents were also able to cap in tests with anti-HGG, anti-K, anti-X, and anti-B cell antibody 41H.16.
In contrast, only a minority of cells with ring fluorescence were able to cap HLA-DR determinants. We performed shedding and resynthesis experiments with normal PBL to determine the percentage of capped cells able both to endocytose and then resynthesize their sIg receptors. Cells able to form caps were also able to resynthesize their receptors after endocytosis (data not shown).
Because the number of HLA-DR-bearing cells able to cap their determinants in an indirect IF assay always correlated closely with the number of sIg' cells, we suspected that this capping subset represented mature sIg' B cells. Using double IF, co-capping of both sIg and HLA-DR determinants was found ( Table I ), indicating that the same subset of PBL express both high density sIg and high density HLA-DR (HLA-DRT).
B cell numbers in PBL from normal donors and patients. Anti-HLA-DR was monoclonal antibody 7H.3; anti-HGG was a conventional antiserum. In the samples of lines 3 and 6, cells were incubated with a mixture of the rabbit and mouse antibodies followed by washing and a second incubation with both the FITC and RITClabeled antibodies. After washing, cells were incubated for 10 min at 370C to allow capping. sIg+ caps seen in the doubly stained samples were considerably larger and more clearly defined than in singly stained samples. In the double caps the patterns and extent of fluorescence of red and green caps were completely identical. ( Table II) . The range of expression in individual samples of PBL is illustrated in Fig. 1 . B cell values for the 51 patients are shown in Table II peripheral blood demonstrates that B cell numbers are even more severely reduced than is apparent from measurements using purified mononuclear cells (Table III) .
To ascertain whether the patient B cells were polyclonal in nature, PBL samples were tested for the number of K-and X-bearing B cells as well as for expression of IgD, IgM, and in a few cases IgG and IgA. In nearly all individual patient PBL samples tested, the B cell population appeared to be polyclonal in the expression of sIg (Table II and Fig. 2) .
Expression ofidiotypic determinants on patient and normal PBL. To more rigorously test for the presence of a small monoclonal subset of lymphocytes in PBL, anti-idiotypic sera were prepared to the monoclonal protein of three patients. Only small numbers (0.04-0.08%) of autologous idiotype positive (Id') PBL were detected (Table IV) .
Fluctuations of B cell levels in individual patients over time. A series of patients have been assessed for B cell levels on a regular basis over a 1-2-yr period and for comparison, a plot of B cell levels over time in three normal donors have been included (Fig. 3, A and B) . Fig. 3 (Table III) .
As an independent measure of the number of B cells in patients, PBL samples were tested for two further classes of surface marker, high density HLA-DR determinants, and expression of a B cell maturation antigen 41H. 16. Two major sets of HLA-DR-positive cells can be distinguished, those that form large very bright polar caps, and those with ring fluorescence. In initial experiments, we demonstrated that in normal subjects cells capping HLA-DR were identical to sIg-capped cells. The low density HLA-DR' cells may represent pre-B or B cell subsets expressing an amount of sIg below the limit of detection in our assay system. In patients categorized by treatment status, the pattern of HLA-DRT and of 41H.16 expression parallelled those of sIg' markers (Table II, Fig. 1 myeloma patients either through the use of anti-idiotypic reagents, or analysis of K/A light chain ratios, or of surface heavy chains (7, 8, (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (Fig. 2) . Although our methods would not reveal the existence of a small population of monoclonal B cells, the results do indicate that the large numbers reported by others (up to 50% of total PBL) (7, 10, 15, (17) (18) (19) can not be detected in PBL from the patient population studied here.
Other workers have detected from 3 to 15% Id' cells in PBL from multiple myeloma patients in remission (7, 10, 17, 19) and much larger numbers in relapse patients (10-47%) (7, 10, 13, 17 
